Kimberly Clark Corp vs Nuwellis Inc — how do they compare? Kimberly Clark Corp trades at $108.57 (market cap $36.11B), while Nuwellis Inc trades at $1.48 (market cap $542.80K). The key difference: Kimberly Clark Corp is far larger — about 66525.4× Nuwellis Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| KMB | NUWE | |
|---|---|---|
Market Cap | $36.11B | $542.80K |
Sector | Consumer Staples | Technology |
52-Week High | $134.81 | $220.50 |
52-Week Low | $93.05 | $1.42 |
Enterprise Value | $41.67B | -$1.27M |
Dividend Yield | 4.72% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →